CARD14 (Caspase Recruitment Domain Family Member 14), also known as CARMA2, is a scaffolding protein that plays a critical role in NF-κB signaling pathways[1]. Originally identified as a regulator of T cell activation, CARD14 has emerged as an important player in neuroinflammation and neurodegenerative diseases through its regulation of inflammatory gene expression[2].
CARD14 functions primarily as a molecular scaffold that assembles signaling complexes:
CARD14 activates NF-κB signaling through assembly of a signaling cascade:
CARD14 contributes to Alzheimer's disease pathogenesis through:
Neuroinflammation: CARD14-mediated NF-κB activation drives expression of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) in glial cells[2:1]. Chronic neuroinflammation is a hallmark of AD.
Amyloid Processing: NF-κB regulated genes can influence amyloid precursor protein (APP) processing and amyloid-beta production.
Blood-Brain Barrier: CARD14 signaling may affect BBB permeability through regulation of inflammatory mediators.
Microglial Activation: CARD14 expression in microglia modulates their inflammatory response to amyloid deposits.
In Parkinson's disease, CARD14 contributes to:
Dopaminergic Neuron Vulnerability: NF-κB activation in dopaminergic neurons can promote apoptosis and enhance vulnerability to α-synuclein toxicity.
Microglial Activation: CARD14-mediated inflammation in microglia contributes to chronic neuroinflammation in the substantia nigra.
α-Synuclein Pathology: Inflammatory pathways activated by CARD14 may accelerate α-synuclein aggregation and propagation.
CARD14 involvement in ALS includes:
Motor Neuron Injury: NF-κB activation in motor neurons and surrounding glia contributes to excitotoxicity and oxidative stress.
Astrocyte Reactivity: CARD14 signaling in astrocytes promotes secretion of inflammatory mediators that harm motor neurons.
TDP-43 Pathology: Inflammatory pathways may interact with TDP-43 proteinopathy in ALS.
CARD14 interfaces with multiple signaling pathways:
CARD14 represents a potential therapeutic target:
Key research areas include:
Jordaan S, et al. CARD14: a potential therapeutic target for inflammatory diseases. Pharmacology & Therapeutics. 2020. 2020. ↩︎ ↩︎
Chen J, et al. NF-κB in Alzheimer's disease: role and therapeutic targeting. Journal of Neuroinflammation. 2022. 2022. ↩︎ ↩︎